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through CD73-expression and adenosine production
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1Center for Oncology and Cell Biology, The Feinstein Institute for Medical Research, 350 
Community Dr., Manhasset, NY 11030 USA
2Center for Molecular Innovation, The Feinstein Institute for Medical Research, 350 Community 
Dr., Manhasset, NY 11030 USA
Abstract
Immune suppression by regulatory T (Treg) cells and regulatory B (Breg) cells is a critical 
mechanism to limit excess inflammation and autoimmunity. IL-10 is considered to be the major 
mediator of B cell-induced immune suppression. Here, we report a novel mechanism for immune 
suppression through adenosine generation by B cells. We identified a novel population of B cells 
that expresses CD73 as well as CD39, two ecto-enzymes that together catalyze the extracellular 
dephosphorylation of adenine nucleotides to adenosine. Whereas CD39 expression is common 
among B cells, CD73 expression is not. Approximately 30–50% of B-1 cells (B220+CD23−) and 
IL-10 producing B (B10) cells (B220+CD5+CD1dhi) are CD73hi, depending on mouse strain, 
whereas few conventional B-2 cells (B220+CD23+AA4.1−) express CD73. In keeping with 
expression of both CD73 and CD39, we found that CD73+ B cells produce adenosine in the 
presence of substrate whereas B-2 cells don’t. CD73−/− mice were more susceptible to dextran 
sulfate sodium salt (DSS)-induced colitis than wild type (WT) mice, and transfer of CD73+ B cells 
ameliorated the severity of colitis, suggesting that B cell CD73/CD39/adenosine can modulate 
DSS-induced colitis. IL-10 production by B cells is not affected by CD73-deficiency. 
Interestingly, adenosine generation by IL-10−/− B cells is impaired due to reduced expression of 
CD73, indicating an unexpected connection between IL-10 and adenosine and suggesting caution 
in interpreting the results of studies with IL-10−/− cells. Together our findings demonstrate a novel 
regulatory role of B cells on colitis through adenosine generation in an IL-10-independent manner.
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Introduction
The balance of pro-inflammatory and anti-inflammatory function is tightly regulated in the 
immune system. Inflammatory reactions must be transient, lasting only until infectious 
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agents are cleared from the body, because excess inflammation can cause tissue damage or 
even autoimmunity (1, 2). Immune cells contain inhibitory populations (3) such as 
regulatory T (Treg) cells (4, 5), regulatory myeloid (Mreg) cells (6, 7) and regulatory B 
(Breg) cells (8–16). A major/central anti-inflammatory factor is IL-10, which suppresses 
production of inflammatory cytokines such as IFN-γ, IL-2, IL-3, TNF-α and GM-SCF from 
macrophages and activated T cells; inhibits IL-6R signaling in a SOCS3-dependent manner; 
diminishes antigen presentation by APC; and, induces IL-10 production (producing a feed-
forward mechanism of IL-10 production) from macrophages and dendritic cells (DC) (17).
During the past decade, accumulating evidence has demonstrated that B cells play a non-
redundant role in the suppression of inflammation as well as the production of protective 
antibodies (8–11). Breg cells were first defined by Kazs and colleagues in hypersensitivity 
model (18). Since then, further studies have revealed that Breg cells can suppress various 
experimental mouse disease entities such as experimental autoimmune encephalomyelitis 
(EAE) (19) (12, 20), collagen-induced arthritis (CIA) (21–23), ovalbumin-induced asthma 
(24), contact hypersensitivity (CHS) (14, 25), TCRα KO, IL-2 KO, and IL-10 KO 
spontaneous colitis (26–28), type 1 diabetes (T1D) (29) and systemic lupus erythematosus 
(SLE) (30) in an IL-10-dependent manner. IL-10 is known to be produced by peritoneal B-1 
(B-1) cells, marginal zone (MZ) B cells, and transitional 2 (T2)-MZ precursor cells upon 
activation (11). A landmark study performed by Yanaba and colleagues showed that IL-10 
secreting B cells (termed B10 cells) are found in the B220+CD1hiCD5+ B cell fraction (14). 
Importantly, this phenotypic profile covers all IL-10 producing B cell populations such as 
B-1 cells, MZ B cells, and T2-MZ precursor cells (11). However, some studies suggest that 
other suppressive factors might be responsible for B cell mediated immune suppression (10). 
Teichmann and colleagues recently reported, using B cell-specific IL-10-deficient mice, that 
IL-10 is not required for amelioration of SLE symptoms (31) although depletion of B cells 
accelerated SLE disease (30). Furthermore, Ray and colleagues suggested an IL-10-
independent mechanism of B cells in EAE recovery (32). Thus, unknown suppressive 
factors other than IL-10 might be involved in B cell-mediated amelioration of SLE and 
EAE.
Treg cells dampen inflammation by secreting IL-10 and TGF-β (33). Recent results indicate 
that, in addition, Treg cells express CD39 and CD73 (34, 35) along with traditional markers 
like Foxp3 and CD25, and suppress inflammation in a CD39- and CD73-dependent manner 
(35). More recently, it was reported that Th17 cells differentiated from naïve T cells with 
IL-6 and TGF-β in vitro also express CD39 and CD73 and this Th17 population plays a 
suppressive role in cancer immunity (36). CD39 and CD73 are ecto-enzymes (37). CD39 
catalyzes the breakdown of extracellular ATP to ADP and AMP while CD73 catalyzes the 
conversion of AMP to adenosine (37). Extracellular ATP plays a pro-inflammatory role 
whereas adenosine plays an anti-inflammatory role (38). Therefore, regulating the balance of 
extracellular ATP and adenosine concentration is important to maintain homeostasis.
Both CD39-deficient (39) and CD73-deficient mice (40, 41) show exaggerated features of 
chemically induced colitis. Furthermore, SNPs in the human CD39 gene are associated with 
the spontaneous colitis, Crohn’s disease (CD) (39). These data suggest CD73 and CD39 play 
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important roles in suppressing colitis in both mouse and human, presumably through 
generation of adenosine.
Mouse B cells can be divided into 2 subsets, acquired-type conventional B-2 cells and 
innate-type B-1 cells, which can be further divided into B-1a cells and B-1b cells according 
to CD5 expression (42). B-1a cells are the primary source of natural antibody which can also 
be contributed by marginal zone B cells whereas B-1b cells contribute long lasting memory 
to some kinds of bacteria or virus infections (43) (44). In addition to CD5, recent studies 
have revealed that B-1 cell populations can be subdivided based on the expression of PD-L2 
(CD273) (45, 46), CD25 (47) and PC1 (also termed ENPP1) (48). It was originally reported 
that CD73 is expressed on a few mouse splenic B cells (49) and more recent data show that 
CD73 is expressed by memory B (Bmem) cells (50, 51). However, whether CD73 is 
expressed by B-1 cells is still unknown although B-1 cells are known to function in a 
regulatory, anti-inflammatory manner (52–56).
Here, we undertook to examine whether B-1 cells express CD73 and whether adenosine 
generation by CD73 is involved in B-1 cell-mediated immunosuppression. We identified a 
novel means of dividing B-1 cells on the basis of CD73 expression. We showed that CD73hi 
B-1 cells generate adenosine, and inhibit experimental colitis. This represents a novel Breg 
mechanism for the anti-inflammatory effect mediated by B cells.
Materials and Methods
Antibodies and reagents
Anti-CD3ε (145-2C11), anti-CD16/CD32 (2.4G2), PE-anti-CD73 (TY23), APC-anti-CD39 
(TÜ66), FITC-anti-CD21/35 (7G6), PE- and APC-anti-PD-L2 (TY25), and FITC-anti-IgMa 
(DS-1) were obtained from BD Biosciences (San Diego, CA, USA). Alexa Flour 647-anti-
CD73 (TY11.8), FITC- and perCP-Cy5.5-anti-B220 (RA3-6B2), perCP-Cy5.5-F4/80, Alexa 
Fluor 647-anti-CD5 (53-7.3), APC-anti-CD93 (AA4.1), and APC-anti-Gr-1 (RB6-8C5) 
were obtained from Biolegend. PE-Cy7-anti-CD23 (2G8) was obtained from Abcam. PE-
anti-IL-10 (JES5–16E3) was obtained from eBioscience (San Diego, CA). Anti-CD40 
(1C10) was obtained from R&D Systems. Affinity-purified F(ab’)2 fragments of goat anti-
mouse IgM (anti-Ig) were obtained from Jackson Immunoresearch Laboratories. LPS from 
Salmonella typhimurium, and 5′-AMP, were obtained from Sigma Aldrich. Adenosine 
Deaminase (ADA) was obtained from Roche Diagnostics (Indianapolis, IN).
Mice
BALB/cByJ, C57BL/6, and CB17 SCID mice, along with IL-10−/− mice on BALB/c, were 
obtained from The Jackson Laboratory (Bar Harbor, ME, USA). CD73-deficient mice 
(CD73−/−) on BALB/c were kindly provided by Dr. Linda Thompson (Oklahoma Medical 
Research Foundation). Mice at 7–10 wk of age were housed at least 1 week before 
experimentation. Mice were cared for and handled in accordance with National Institutes of 
Health and institutional guidelines.
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Flow cytometry
Cell surface phenotype was analyzed as previously described (57). In brief, cells pre-treated 
with 2.4G2 (5 μg/ml) were incubated with fluorescence-conjugated monoclonal antibodies 
in staining buffer (PBS containing 2% FCS and 0.05% NaN3) on ice for 30 min and then 
washed with staining buffer. Stained cells were analyzed on a FACSCalibur or LSR II (BD 
Biosciences) or Gallios (Beckman Coulter) instrument. In some experiments, 7-amino-
actinomycin D (1 μg/ml) (BD Biosciences) was used to exclude dead cells from analysis. 
For each sample, at least 1 × 104 cells were collected and were analyzed with Flowjo 
software (Tree Star). Compensation was adjusted with Flowjo software using none-staining 
and single color staining controls for each flow experiment.
Purification of CD73hi and CD73lo B-1 cells, and B-2 cells
CD73hi and CD73lo B-1 cell populations were obtained by sort-purifying 
B220+CD23−/loCD73hi and B220loCD23−/loCD73lo cells from peritoneal washouts with an 
Influx instrument (Becton Dickinson), respectively. Splenic B-2 cells (B-2S) were obtained 
by sort-purifying B220+AA4.1−CD21loCD23hi cells from spleen cell suspensions. Cells 
were cultured in RPMI 1640 medium (HyClone) containing 10% FCS, 10 mM HEPES, 2 
mM L-glutamine, 0.1 mg/ml penicillin and streptomycin, and 50 μM 2-ME (complete 
medium) or in X-VIVO 10 medium (Lonza) containing 10 mM HEPES, 2 mM L-glutamine, 
0.1 mg/ml penicillin and streptomycin, and 50 μM 2-ME (serum-free medium).
Measurement of adenosine by CREB reporter assay using CHO-ADORA2B cells
Sort-purified cells (1 × 105) were incubated in 96-well microtiter plates in 200 μL of X-
VIVO 10 serum free medium (Lonza) for the indicated times with or without AMP or ATP. 
Supernatants were then harvested and kept at −20°C until analysis. Adenosine receptor A2B 
(ADORA2B) stimulation of CREB, reflected in CREB-driven luciferase activity was used 
as the readout for adenosine in supernatants. In brief, PathDetect pCRE-luc Cis-Reporter 
Plasmid (Agilent Technologies) and pRL-TK vector (Promega) were co-transfected into 
Chinese Hamster Ovary (CHO) cells that overexpress adenosine receptor A2B (CHO-
ADORA2B) (DiscoveRx), using Amaxa Nucleofector (Lonza) according to the 
manufacturer’s instructions. Transfected cells were cultured in F-12K medium (ATCC) 
containing 10% FCS, 10 mM HEPES, 2 mM L-glutamine, 0.1 mg/ml penicillin and 
streptomycin for 24 hr at a density of 1 × 104 cells/100 μL/well in 96-well microtiter plates. 
After washing transfected cells with X-VIVO 10 twice, supernatants from primary cell 
cultures were incubated with pCRE-luc transfected CHO-ADORA2B cells for 4 hr. 
Luciferase activity in cell lysates was analyzed by the Dual-Luciferase Reporter Assay 
System (Promega) according to the manufacturer’s instructions, using a 20/20n Single Tube 
Luminometer (Turner Biosystems), as previously reported (46). Relative luciferase activity 
was calculated as firefly-luciferase activity/renilla-luciferase activity. Concentrations of 
adenosine were calculated using a standard regression curve generated using adenosine 
(Sigma) diluted in culture medium.
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Measurement of adenosine by HPLC
Sort-purified cells (1 × 106) were incubated in 24-well plates in 1 mL of X-VIVO 10 serum 
free medium for 2 hr with or without AMP or ATP. Supernatants were then harvested and 
kept at −20°C until analysis. Phenylboronic acid was added to the supernatants which were 
then incubated at room teperature for 20 hr. Each sample was extracted with EtOAc 3 times 
and the combined organic portion was concentrated and dried under a nitrogen stream and 
then dissolved in pyridine. Acetic anhydride was added and the solution was incubated at 
60°C for 2 hr. The solvent was removed under a nitrogen stream and the residue was dried 
with vacuum pump for 20 hr. The dried residue was dissolved in methanol and injected 
directly for HPLC analysis (Waters 600 Controller and Waters 996 Photodiode Array). 
Column type: Phenomenex Luna 5u C18 (2) 100A 250 × 4.6 mm. Flow rate: 1 ml/min with 
a linear gradient from water (0.05% TFA): MeOH (0.05% TFA) [90:10] to water (0.05% 
TFA): MeOH (0.05% TFA) [10:90] in 20 min. Wavelength: 256nm.
Adoptive transfer into SCID
Sort-purified CD73hi and CD73lo B-1 cells, or total B-1 cells, were washed with PBS twice 
and then suspended in PBS. B-1 cells (1 × 106) were i.p. injected into CB17 SCID mice. 
Mice were sacrificed 2 weeks after the transfer and CD73 expression on B-1 cells was 
analyzed by flow cytometry after re-staining with fluorescently labeled anti-CD73.
DSS mouse colitis model
Mice were administered 5 % dextran sodium sulfate (DSS, molecular size range 36 to 50 
kDa, MP Biomedicals) in drinking water for 7 days, followed by normal drinking water. The 
parameters for colitis evaluation recorded in the experiments were body weight, colon 
length, and colon density. In some experiments, total colon proteins were extracted using 
lysis buffer (200 mM NaCl, 5 mM EDTA, 10 mM Tris, 10 % glycine) containing Complete 
Protease Inhibitor Cocktail (Roche Diagnostics) and ground with Sample Grinding Kit (GE 
Healthcare) according to the manufacturer’s instructions. In some experiments, sort-purified 
B-1 cells (B220loCD23−/lo) were washed with PBS twice and then suspended in PBS and (1 
× 106) i.p. injected into CD73−/− mice a week before DSS administration.
IL-1β
Colon protein lysates were evaluated for content of IL-1β by ELISA (eBioscience) 
according to manufacturer’s instructions.
Statistics
All quantitative data are expressed as mean ± SEM. Student’s t-test was used for statistical 
determinations. Values of p<0.05 are considered statistically significant (*p<0.05, **p<0.01 
or ***p<0.001, as indicated in figure legends).
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Results
Peritoneal B-1 cells express CD39 and CD73
We investigated whether B-1 cells express CD39 and CD73, cell surface ectoezymes that 
together can generate immunosuppressive adenosine. Splenocytes and peritoneal cells from 
male C57BL/6 mice were tested for surface expression of these molecules by 
immunofluorescent staining and flow cytometry. Although all B cells express CD39 (Fig. 
1A), we found expression of CD39 on B-1 cells to be 3-fold higher than that of peritoneal 
B-2 (B-2P) cells and splenic B-2 (B-2S) cells (Fig. 1B). In contrast, expression of CD73 is 
much more restricted. We found that CD73 is expressed on about half of B-1 cells but on 
very few conventional B-2P or B-2S cells (Fig. 1C). Overall, B-1 cell expression of CD73 is 
5-fold higher than expression of CD73 by peritoneal and splenic B-2 cells (Fig. 1D). The 
intensity of immunofluorescently stained CD73 in B-1 cells bearing low amounts of CD73 is 
still a little higher than isotype control staining (Fig. 1C), and there was no staining for 
CD73 above isotype control when B-1 cells from CD73−/− mice were examined (Fig. 1E), 
indicating that the minor shift of CD73 intensity in the CD73 low fraction is due to a very 
small degree of CD73 expression and is not due to non-specific-binding. On this basis we 
subdivided B-1 cells into two populations that express high (CD73hi B-1 cells) and low 
(CD73lo B-1 cells) amounts of CD73. B-1 cells from male BALB/c mice show a pattern of 
CD73 and CD39 expression that is similar to B-1 cells from male C57BL/6 mice (Fig. S1 
A–D). We analyzed CD73 and CD39 expression on B cells from female BALB/c and 
C57BL/6 mice and didn’t find any difference between male and female cells (data not 
shown). These results indicate that higher expression of CD39, and bimodal expression of 
CD73 and CD39, by B-1 cells are not strain nor gender specific.
CD73 expression is not an inducible marker
We tested the possibility that CD73 expression on CD73hi B-1 cells may be transient, and/or 
that CD73 expression can be upregulated on CD73lo B-1 cells or CD73− B-2S cells. CD73hi 
and CD73lo B-1 cells and B-2S cells were sort-purified and were then cultured with or 
without B cell mitogens for 72 hr, after which B cells were re-stained with anti-CD73. We 
found that CD73 expression did not change in any of the B cell populations during culture 
without stimulation (Fig. 2A and 2B). Furthermore, there was almost no enhancement of 
CD73 expression from CD73lo B-1 cells nor CD73− B-2S cells after mitogen stimulation 
with anti-Ig, or anti-CD40 (Fig. 2A and 2B). Although CD73 expression was a little affected 
by Anti-Ig or anti-CD40 stimulation, LPS stimulation downregulated CD73 expression (Fig. 
2A and 2B). Next, sort-purified CD73hi and CD73lo B-1 cells were adoptively transferred 
into CB17 SCID. After 2 weeks, peritoneal washout cells were collected and expression of 
CD73 by B-1 cells was examined by immunofluorescent staining and flow cytometry. We 
found that CD73 expression stayed low when CD73lo B-1 cells were transferred (Fig. 2C 
and 2D) and most of CD73 expression stayed high when CD73hi B-1 cells were transferred 
(Fig. 2C and 2E). However, we observed that CD73 expression on some CD73hi B-1 cells 
decreased presumably due to environmental factors such as LPS derived from commensal 
bacteria, which downregulated CD73 expression in vitro (Fig. 2A and 2B). These results 
suggest that CD73 expression on CD73hi B-1 cells can be downregulated after activation 
and that CD73 expression on CD73lo B-1 cells or CD73- B-2 cells are not inducible.
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CD73hi and CD73lo B-1 cells are similar in many functional characteristics
We characterized CD73hi and CD73lo B-1 cell populations further by examining several 
phenotypic and functional features. We found that CD73hi and CD73lo B-1 cells are similar 
in terms of cell size (FSC) and cell density (SSC), and of surface expression of IgM, IgD, 
Mac1, B220, PD-L2 and CD23 as detected by immunofluorescent staining and flow 
cytometry (Fig. S2A). There was also no difference in phosphatidylcholine (PtC) binding 
between CD73hi and CD73lo B-1 cells (Fig. S2B), with the variance between PD-L2+ and 
PD-L2− B-1 cells (45) providing a positive control (Fig. S2C). There was no significant 
difference in CD73 expression levels between B-1a cells and B-1b cells (data not shown). 
We evaluated induction of IL-10 secretion by intracellular staining after stimulation by 
PMA or LPS and again found no difference between CD73hi and CD73lo B-1 cells (Fig. 
S2D). We further examined proliferative responses by thymidine incorporation with a 
variety of mitogenic stimuli and found similar positive responses to PMA, LPS and anti-
CD40, which are known B-1 cell mitogens (58) with little or no response to BCR 
crosslinking, as expected (59) (data not shown).
We determined the capacity for B-1 cell immunoglobulin secretion by ELISA quantification 
of IgM in serum collected from CB17 SCID mice 2 weeks after transfer of CD73hi or 
CD73lo B-1 cells (Fig. 2B). We found no difference in IgM levels between the 2 recipient 
groups (data not shown), indicating that CD73hi and CD73lo B-1 cells both spontaneously 
secrete natural IgM antibody and do so similarly. Collectively, these results indicate that B-1 
cell expression of CD73 does not correlate with differences in numerous known phenotypic 
or functional B-1 cell characteristics.
CD73hi B-1 cells produce substantially more adenosine than CD73lo B-1 cells
Next, we focused on CD73 enzyme activity. CD73 converts AMP to adenosine outside cells 
(37). CD73hi and CD73lo B-1 cells, and B-2S cells, were sort-purified and cultured with or 
without the indicated concentrations of AMP in serum-free medium for 2 hr. Supernatants 
were harvested and tested for adenosine. To measure adenosine in supernatant fluids we 
established a CREB luciferase reporter assay using CHO-ADORA2B cells (see Materials 
and Methods). This new method relies on induction of CREB activation by adenosine. We 
demonstrated that activation of the CREB luciferase reporter is very sensitive because the 
assay reliably measures adenosine concentrations above 0.01 μM (Fig. S3A). We calculated 
the concentration of adenosine using a standard regression curve generated by diluting 
adenosine in culture medium. The firefly luciferase activity was completely blocked by 
pretreatment of ADA, indicating that this new adenosine detection method using CHO-
ADORA2B cells and CREB luciferase reporter is very specific to adenosine generation (Fig. 
3A). We found that CD73hi B-1 cells produced substantially more adenosine in response to 
increasing doses of AMP than did CD73lo B-1 cells (Fig. 3B). In direct contrast, B-2S cells 
didn’t produce any adenosine at any dose of AMP (Fig. 3B). We confirmed these results by 
HPLC analysis (Fig. S3B). All together these findings indicate that CD73 on B-1 cells is a 
functional ectoenzyme and that higher levels of CD73 on CD73hi B-1 cells produce much 
more adenosine in response to extracellular AMP as compared to CD73lo B-1 cells and B-2S 
cells.
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CD73 expressed by B-1 cells ameliorates DSS-induced acute colitis
We evaluated the role of B-1 cells and B-1 cell CD73 in vivo. We examined DSS-induced 
colitis in mice because suppression of this condition has been shown in separate studies to 
be dependent on B cells (26, 27, 52), and to require adenosine produced through CD39 and 
CD73 enzyme activity (39–41). Consistent with the latter, CD73−/− mice are more 
susceptible to DSS-induced colitis than WT mice (41), whereas B-1 cell numbers are 
normal. Bynoe and colleagues reported that after DSS administration, CD73−/− mice lose 
more weight and exhibit colons characterized by shorter length, higher density, and more 
IL-1β, resulting from increased colonic inflammation, as compared to control (41), which 
we confirmed in preliminary experiments (Fig. 4A). We hypothesized that DSS-induced 
colitis would be suppressed by B-1 cells bearing CD73, that are capable of generating 
adenosine. To test this hypothesis, we adoptively transferred BALB/c B-1 cells to CD73−/− 
mice 7 days before administration of DSS. We found that DSS administration to CD73−/− 
mice that had received B-1 cells resulted in less severe colitis in comparison to CD73−/− 
mice that instead had received only PBS, as evidenced by reduced weight loss (Fig. 4A), 
increased colon length (Fig. 4B) and diminished colon density (Fig. 4C). Further, B-1 cell 
transfer reduced IL-1β levels in colonic extracts of DSS-treated CD73−/− mice as compared 
to PBS-treated CD73−/− mice (Fig. 4D) although we didn’t find any significant differences 
in IL-10 and TNF-α levels in colonic extracts (data not shown). However, these parameters 
still reflected more inflammation than was present in DSS-treated WT (CD73+/+) mice (Fig. 
4A–D). Regardless, these results strongly suggest that CD73 on B-1 cells is responsible for 
reducing the severity of experimental inflammatory colitis.
IL-10−/− B-1 cells produce less adenosine due to reduced expression of CD73
Like B-1 cells, Treg cells also express CD73 (35). Very recently, Ring and colleagues 
reported that Treg cells from IL-10−/− mice fail to generate adenosine in the presence of 
ATP, suggesting an unexpected connection between IL-10 and adenosine production (60). 
We investigated the possibility that adenosine production by B-1 cells may be affected by 
IL-10 just like Treg cells. We sort-purified B-1 cells from WT or IL-10−/− mice and cultured 
B-1 cells with or without the indicated concentrations of AMP for the indicated times, after 
which supernatants were harvested and analyzed for adenosine by CREB reporter assay. 
Intriguingly, we found adenosine generated by B-1 cells from IL-10−/− mice was reduced 
50–70 % compared to that from WT B-1 cells at any concentration of AMP or ATP 
substrate at any time point (Fig. 5A–B, and data not shown). This difference was not due to 
altered cell viability because B-1 cells from both WT and IL-10−/− mice were 80–95 % 
viable during the period of cell culture (data not shown). We next analyzed CD39 and CD73 
surface expression on IL-10−/− B-1 cells. Surprisingly, we found that CD73 expression was 
much lower on IL-10−/− B-1 cells as compared to WT B-1 cells (p<0.01; Fig. 6A, B and C), 
whereas CD39 expression trended slightly higher although this difference was not 
statistically significant (p=0.06) (Fig. 6D and E). Taken together, these results indicate that 
IL-10−/− B-1 cells generate less adenosine and that this is due to reduced expression of 
CD73, as compared to WT B-1 cells. B10 cells are characterized by CD5+CD1dhi B cells 
and IL-10 production after activation. We hypothesized that B10 might express CD73 
because CD5+CD1dhi B cells include splenic B-1a cells. To test this idea, we analyzed 
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CD73 expression on CD5+CD1dhi B cells. As we expected, about 30 % of splenic B10 cells 
expressed CD73 (Fig. 6F). Interestingly, CD73 expression was much lower on IL-10−/− B10 
cells as compared to WT B10 cells (Fig. 6F). In contrast, as reported by Ring and 
colleagues, CD73 expression by IL-10−/− Treg cells was comparable to that of IL-10+/+ Treg 
cells (Fig. 6G) (60), suggesting that the reduction of CD73 expression on IL-10−/− mice is a 
defect specific to B cell populations.
Discussion
Here we identified, for the first time, expression of the 5′-nucleotidase, CD73, by B-1 cells 
and B10 cells, thereby distinguishing CD73hi and CD73lo subsets and marking a new way to 
divide this population. In contrast to B-1 cells and B10 cells, CD73 is not expressed by 
conventional B-2 cells. CD73 is an ectoezyme considered capable of generating adenosine 
from AMP. We showed that CD73hi but not CD73lo B-1 cells produce adenosine in vitro 
when substrate is provided, and that CD73+ but not CD73− B-1 cells suppress inflammation 
associated with DSS-induced colitis in vivo. Together these results describe a new 
mechanism for immunosuppression by a select subset of the small B-1 cell population, 
separate and apart from IL-10 secretion. CD73hi B-1 cells may thus be considered a novel 
type of Breg cell.
CD73 expression by CD73hi B-1 cells is stable, and CD73 is not induced on CD73− B-1 
cells by a variety of B cell mitogens, suggesting that CD73 is not an activation marker. 
Rather, CD73 identifies a specific CD73hi subset that differs little from CD73− B-1 cells in 
many functional parameters with the notable exception of ectoezyme activity. However, 
CD73 expression is not the only surface antigen that distinguishes B-1 cell subpopulations, 
as B-1 cell phenotypic heterogeneity extends to expression of PD-L2 (45), CD80 (61), CD25 
(47), PC1 (48) and CD5 (42). Interestingly, Shlomchik’s group recently reported that CD73, 
PD-L2 and CD80 are expressed by some memory B (Bmem) cells, suggesting that Bmem 
cells are phenotypically heterogeneous (50, 51), much like B-1 cells. The similarity between 
B-1 cells and Bmem cells with respect to expression of CD73, PD-L2 and CD80 may relate 
to developmental selection by antigen in both populations and suggests that some B-1 cells 
might be Bmem cells or that some Bmem cells might derive from B-1 cells. The existence of 
memory function within the B-1 cell pool has been delineated by recent work from 
Herzenberg and colleagues which supports the existence of memory B-1 (B-1mem) cells 
(62, 63). Further studies will be required to elucidate connections that may be present 
between these two populations.
CD73hi B-1 cells concurrently express the ATP-diphosphohydrolase, CD39, a ubiquitous 
surface antigen and ectoenzyme that convert ATP to ADP and AMP. Coordinated 
expression of CD39 and CD73 on B-1 cells is capable of generating adenosine from 
extracellular ATP as well as AMP, as we have shown (Fig. 3, 5, and data not shown). These 
latter molecules leak from dead and dying cells during an inflammatory response, and so 
with respect to CD73hi B-1 cells, inflammation may seed its own feedback inhibition (Fig. 
7). ATP may also be actively released (64) and/or secreted by commensal bacteria (65); 
considering the peritoneal location of murine B-1 cells, adenosine generation may play a 
role under normal circumstances in circumventing potential immune responses against gut 
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bacteria, as suggested by the ability of B-1 cells to ameliorate DSS-induced colitis in CD73-
deficient animals (Fig. 4). The ectoezyme/adenosine mechanism of immunosuppression is 
clearly distinct from IL-10-mediated immune inhibition, although the B-1 cell population 
participates in both. Although IL-10 has been considered to be a major inhibitory factor of 
B-cell mediated immune suppression, we suggest that CD73-mediated adenosine production 
by B cells may play a more important role than IL-10 in opposing inflammation in vivo, for 
several reasons. First, the absolute number of IL-10 secreting cells is extremely limited in 
the steady state (8), whereas 30–50 % of resting B-1 cells (Fig. 1) and B10 cells (Fig. 6) 
express CD73. Second, potent IL-10 secretion requires strong stimulation such as that 
provided by anti-CD40 + LPS + PMA + Ionomycin (8), whereas CD73-mediated adenosine 
production is constitutive so long as substrate is present (Fig. 5). In keeping with this, 
Teichmann and colleagues recently reported that lineage-specific deletion of IL-10 from B 
cells does not alter disease progression in a mouse model of lupus (31), suggesting that 
another activity of B cells, such as B-1 expression of CD73, may mediate suppression. 
Further, CD73hi B-1 cells may be more potent in suppressing inflammation than Treg cells, 
considering that transfer of Treg cells didn’t ameliorate the severity of colitis in these mice 
(41).
Despite the distinction between CD73- and IL-10-mediated immune suppression, these two 
mechanisms appear to be linked. IL-10 deficiency affects both Treg (60) and CD73hi B-1reg 
cells in ways that reduce adenosine generation and thus adenosine-mediated 
immunosuppression. In B-1 cells this results from a straightforward reduction in CD73 
expression (Fig. 6), whereas in Treg cells CD73 expression is not affected and the 
mechanism is less well defined. Regardless of mechanism, this interaction affects the 
interpretation of studies conducted with IL-10-deficient animals. Loss of 
immunosuppression in the absence of IL-10 has been invoked often to support an IL-10-
dependent regulatory pathway in inflammatory diseases and disease models including colitis 
(26, 28), EAE (12, 20), CIA (21–23), asthma (24), CHS (14, 25), T1D (29) and SLE (30). 
However, our results and the results of others raise the possibility that the true mediator of 
immunosuppression is adenosine, the generation of which is impaired in by IL-10 
deficiency, which now must be considered in studies that rely on IL-10−/− mice and/or 
tissues.
The molecular mechanism by which CD73 expression is regulated in B-1 cells remains 
unknown. Recent results on Th17 cells differentiated in vitro indicate that expression of 
CD73 and CD39 is upregulated by IL-6-induced STAT3 activation and TGF-β-induced 
Gfi-1 downregulation, with both transcription factors binding to the ectoenzyme promoters; 
this results in production of an immunosuppressive Th17 effector cell (36). B-1 cells 
constitutively express activated, phosphorylated STAT3 (66) and this may predispose to 
constitutive CD73 expression, although it is not known whether B-1 cells that express CD73 
are the same that express pSTAT3.
A role for adenosine in immune regulation by B cells is emphasized by the recent report that 
up to 90% of human circulating B cells co-express CD73 and CD39 and generate adenosine 
(67). Although the particular B cell populations that express CD73/CD39 have not been 
delineated, the situation in human B cells stands in contrast to mouse B cells, where only a 
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portion of the small B-1 cell population and some memory B cells co-express CD73 and 
CD39. It is unclear at the present time whether a larger fraction of human B cells can 
actively participate in adenosine-mediated immunosuppression as compared to mouse B 
cells, or whether only a fraction of CD73-bearing human B cells is immunosuppressive, 
such as the recently identified human B-1 cell population that may express higher levels of 
CD73 than human conventional B cells (68). Inasmuch as CD39-expession is not 
accompanied by co-expression of CD73 among most human circulating T cells (67), it may 
be that adenosine-mediated immunosuppression is a dominant mode of effector cell immune 
inhibition for B cells but not other cell types.
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Figure 1. 
CD73 and CD39 are expressed by B-1 cells. Peritoneal cavity cells and spleen cells obtained 
from C57BL/6 mice were immunofluorescently stained with anti-CD39 (A, B) or anti-CD73 
(C, D, E) or isotype control (A–E), as indicated, and analyzed by flow cytometry. B-1 cells 
from the peritoneal cavity were identified as B220+ CD23lo. B-2 cells from the peritoneal 
cavity (B-2P) were identified as B220+ CD23hi. B-2 cells from the spleen (B-2S) were 
identified as B220+CD93−CD21loCD23hi. Results are representative (A, C) or inclusive (B, 
D) of 5 mice. Mean fluorescence intensity (MFI) of stained CD39 (B) or CD73 (D) was 
calculated by flowjo. (E) Peritoneal cavity cells from CD73+/+ (upper panel) or CD73−/− 
(lower panel) mice were immunofluorescently stained with anti-CD73 (line) or isotype 
control (dashed line) and CD73 expression on B-1 cells is shown. Results are representative 
of 3 independent experiments.
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Figure 2. 
CD73 expression on B-1 cells is stable in vitro and in vivo. (A) Sort-purified CD73hi or 
CD73lo B-1 cells, or B-2S cells, were cultured for 72 hours with or without anti-Ig (10 μg/
ml), LPS (10 μg/ml) or anti-CD40 (2 μg/ml) in complete RPMI medium. Cells were 
harvested and re-stained with anti-CD73 or isotype control, as indicated, and analyzed by 
flow cytometry. Results are representative or inclusive (B) of 2 independent experiments. 
(C) (D) Sort-purified CD73hi or CD73lo B-1 cells (1 × 106) were adoptively transferred i.p. 
into CB17 SCID mice. After 2 weeks, peritoneal cavity cells were immunofluorescently 
stained with anti-CD73 and anti-B220 and analyzed by flow cytometry. Results are 
representative (C) or inclusive (D) (E) of 4 recipient mice. The percentage of CD73lo (D) or 
CD73hi (E) B-1 cells before or after transfer are shown, respectively.
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Figure 3. 
Adenosine is produced by CD73hi B-1 cells in the presence of 5′AMP in vitro. (A) Sort-
purified total B-1 cells were cultured in serum-free X-VIVO medium with or without the 
indicated concentrations of 5′AMP for 2 hours. Some cells were pretreated with 0.1 U/ml of 
ADA (B) Sort-purified CD73hi or CD73lo B-1 cells, or B-2S cells, were cultured in serum-
free X-VIVO medium with or without the indicated concentrations of 5′AMP for 2 hours. 
Supernatants were harvested and adenosine levels were measured by CREB luciferase 
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reporter assay using CHO-ADORA2B cells. Data shown are mean values ± SEM from 4 (A) 
and 8 (B) independent experiments, respectively.
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Figure 4. 
WT B-1 cells confer resistance to DSS-induced colitis in CD73−/− mice. B-1 cells (1 × 106) 
from WT (CD73+/+) mice were i.p. injected into CD73−/− mice or CD73−/− mice were given 
PBS i.p., a week before DSS treatment began. Mice were administered 5 % DSS in drinking 
water for 7 days, followed by normal drinking water. (A) Body weight was monitored and is 
shown as the percent of initial weight prior to DSS (mean ± SEM). Student’s t-test was used 
to analyze the significance of the weight loss of CD73−/− mice that had received B-1 cells 
(▲) compared to CD73−/− mice that instead had received only PBS (■).
(B) Colon length and weight were recorded 1 week after the end of DSS administration. 
Colon length is shown. (C) Colon density was calculated as weight/length and is shown. (D) 
Proteins were extracted from colonic tissue and IL-1β levels were quantified by ELISA. 
Data shown are mean values ± SEM from at least 5 mice for each group (A–D) pooled from 
2 independent experiments.
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Figure 5. 
IL-10−/− B-1 cells produce less adenosine in the presence of AMP in vitro than WT B-1 
cells. Sort-purified B-1 cells from WT (IL-10+/+) (circle) or IL-10−/− mice (square) were 
cultured in serum-free X-VIVO medium for 2 hrs with or without the indicated 
concentrations of AMP (A), or were cultured in serum-free X-VIVO medium with 100 μM 
AMP (B) for the indicated times. Adenosine levels in supernatants were measured by CREB 
luciferase reporter assay using CHO-ADORA2B cells. Data shown are mean values ± SEM 
from 8 independent experiments.
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Figure 6. 
CD73 expression on B-1 cells and B10 cells is impaired in IL-10−/− mice. (A–E) Peritoneal 
cavity cells from WT (IL-10+/+) or IL-10−/− mice were immunofluorescently stained to 
identify B-1 cells (B220+ CD23lo) and to gauge expression of CD73 (A) and CD39 (D) by 
flow cytometry. The fraction of CD73-expressing B-1 cells (B), and mean fluorescence 
intensity (MFI) of CD73 (C) or CD39 (E) expression on B-1 cells were calculated with 
flowjo. (F) (G) WT splenocytes were immunofluorescently stained to identify B10 
(B220+CD5+CD1dhi) (F) and Treg cells (CD4+CD25+) (G) and to gauge expression of 
CD73. Results are representative of 3 mice.
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Figure 7. 
Model of B cell-mediated anti-inflammation thorough CD73/adenosine. In areas of ongoing 
inflammation, ATP is released from dead or dying cells. At such sites, ATP is converted to 
adenosine through CD73-expressing B cells. Extracellular adenosine can suppress ongoing 
inflammation to maintain homeostasis. Our results also indicate that IL-10 is a positive 
regulator of CD73 expression on B cells.
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